ONCY Stock Forecast: Oncolytics Biotech, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Oncolytics Biotech, Inc. is $4.98. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Oncolytics Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (84): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (12): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ONCY stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ONCY, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 19 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $5.00 |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Aug 2025 | Lake Street | Initiates | Buy | — |
| 21 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 May 2025 | Jones Trading | Downgrade | Hold | — |
| 10 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Mar 2025 | Maxim Group | Maintains | Buy | — |
| 10 Mar 2025 | RBC Capital | Maintains | Outperform | — |
| 3 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Apr 2024 | Raymond James | Initiates | Outperform | — |
| 8 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Feb 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Jan 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Jan 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ONCY.
This page is one stock. Monday covers all of them.
ONCY appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ONCY vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Oncolytics Biotech, Inc. returned −64.5% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ONCY analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −211.2%
- Dividend yield
- —
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Oncolytics Biotech, Inc. has a market value of $53.1M and an enterprise value of $43.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$38.2M.
Free cash flow in the twelve months to 30 June 2026: −$26.7M.
Oncolytics Biotech, Inc. employs 29 people.
Data provided by Twelve Data
ONCY and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ONCY’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Oncolytics Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ONCY
What is the ONCY stock price forecast for 2026-2027?
The median 12-month analyst price target for Oncolytics Biotech, Inc. is $4.98, with estimates ranging from $2.83 to $5.82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ONCY stock a buy right now?
Of the 5 analysts covering Oncolytics Biotech, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oncolytics Biotech, Inc. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ONCY?
As at 21 Nov 2026, Oncolytics Biotech, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (84 of 100).
Will ONCY stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $4.98, and Ticker Nerd's factor model ranks Oncolytics Biotech, Inc. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ONCY stock forecast for 2030?
No analyst covering Oncolytics Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ONCY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.83 to $5.82 over the next 12 months.
How has ONCY stock performed over the past year?
Oncolytics Biotech, Inc. returned -64.5% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Oncolytics Biotech, Inc. do?
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent designed to stimulate the innate and adaptive immune systems against cancer. The company’s current programs center on solid tumors and hematological malignancies, with particular emphasis on gastrointestinal cancers such as colorectal, pancreatic, and anal cancers, as well as hormone receptor-positive, HER2-negative breast cancer.
About Oncolytics Biotech, Inc.
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent designed to stimulate the innate and adaptive immune systems against cancer. The company’s current programs center on solid tumors and hematological malignancies, with particular emphasis on gastrointestinal cancers such as colorectal, pancreatic, and anal cancers, as well as hormone receptor-positive, HER2-negative breast cancer. Its research approach combines pelareorep with chemotherapy and immune checkpoint inhibitors to improve how tumors respond to treatment. Oncolytics Biotech also advances clinical studies and regulatory development efforts through its pipeline and strategic collaborations, positioning the company within the oncology immunotherapy market.
CEO Mr. Jared Kelly J.D., L.L.M. · 29 employees · United States · https://oncolyticsbiotech.com